See more : Plasto-Cargal Group Ltd (PLCR.TA) Income Statement Analysis – Financial Results
Complete financial analysis of Zogenix, Inc. (ZGNX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Zogenix, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Russel Metals Inc. (RUS.TO) Income Statement Analysis – Financial Results
- QUEST CAPITAL MARKETS LIMITED (QUESTCAP.BO) Income Statement Analysis – Financial Results
- Reach Messaging Holdings, Inc. (RCMH) Income Statement Analysis – Financial Results
- Ilkka Oyj (ILK1S.HE) Income Statement Analysis – Financial Results
- Hang Yick Holdings Company Limited (1894.HK) Income Statement Analysis – Financial Results
Zogenix, Inc. (ZGNX)
About Zogenix, Inc.
Zogenix, Inc., a biopharmaceutical company, develops and commercializes therapies to transform the lives of patients and their families living with rare diseases in the United States. The company's lead product candidate is the Fintepla, a low-dose fenfluramine, which is in Phase III clinical trials for the treatment of seizures associated with Dravet syndrome, as well as to treat seizures associated with Lennox-Gastaut syndrome; and that is in Phase II clinical trials for the treatment of other rare epileptic syndromes and diseases. It is also developing MT1621, an investigational therapy for the treatment of a rare genetic disorder called thymidine kinase 2 deficiency. Zogenix, Inc. has a collaboration with Tevard Biosciences for the research, development and commercialization of novel gene therapies for Dravet Syndrome and other genetic epilepsies. The company was formerly known as SJ2 Therapeutics, Inc. and changed its name to Zogenix, Inc. in August 2006. Zogenix, Inc. was incorporated in 2006 and is headquartered in Emeryville, California.
| Metric | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 81.69M | 13.64M | 3.65M | 0.00 | 9.82M | 28.85M | 27.18M | 40.53M | 33.01M | 44.33M | 37.58M | 23.44M | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 4.83M | 542.00K | 0.00 | 0.00 | 10.73M | 22.47M | 22.70M | 31.88M | 22.48M | 20.85M | 20.50M | 13.69M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 76.86M | 13.10M | 3.65M | 0.00 | -908.00K | 6.38M | 4.48M | 8.65M | 10.53M | 23.48M | 17.08M | 9.75M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 94.08% | 96.03% | 100.00% | 0.00% | -9.25% | 22.12% | 16.49% | 21.35% | 31.89% | 52.96% | 45.45% | 41.60% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 142.66M | 138.00M | 115.64M | 100.93M | 67.45M | 41.84M | 27.86M | 18.94M | 12.81M | 21.41M | 33.04M | 28.64M | 21.44M | 33.91M | 24.33M | 4.90M |
| General & Administrative | 0.00 | 99.57M | 33.63M | 23.22M | 21.12M | 20.99M | 22.41M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Selling & Marketing | 0.00 | 0.00 | 27.17M | 15.73M | 4.76M | 6.00M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 148.52M | 99.57M | 60.79M | 38.95M | 25.89M | 27.00M | 26.35M | 88.90M | 50.04M | 49.49M | 60.46M | 51.27M | 14.10M | 11.82M | 4.73M | 1.47M |
| Other Expenses | 7.89M | 3.94M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -10.00K | 10.00K |
| Operating Expenses | 299.07M | 241.52M | 176.43M | 139.88M | 93.33M | 68.84M | 54.21M | 107.84M | 62.85M | 70.91M | 93.50M | 79.91M | 35.54M | 45.73M | 29.05M | 6.38M |
| Cost & Expenses | 303.90M | 242.06M | 176.43M | 139.88M | 104.06M | 91.30M | 76.91M | 139.71M | 85.33M | 91.76M | 114.00M | 93.60M | 35.54M | 45.73M | 29.05M | 6.38M |
| Interest Income | 659.00K | 2.89M | 9.80M | 7.17M | 1.09M | 443.00K | 0.00 | 20.00K | 18.00K | 53.00K | 37.00K | 5.00K | 10.00K | 696.00K | 0.00 | 0.00 |
| Interest Expense | 15.28M | 3.76M | 2.00K | 6.00K | 2.64M | 2.83M | 0.00 | 3.09M | 6.61M | 10.31M | 7.64M | 10.01M | 9.19M | 1.72M | 1.35M | 980.00K |
| Depreciation & Amortization | 9.46M | 5.47M | 1.27M | 155.00K | 425.00K | 1.40M | 1.62M | 1.63M | 1.81M | 1.60M | 1.58M | 1.43M | 5.31M | 1.10M | 410.00K | 1.96M |
| EBITDA | -202.58M | -217.58M | -418.23M | -123.75M | -123.75M | -66.43M | 11.86M | 13.39M | -72.44M | -35.47M | -74.68M | -62.11M | -31.39M | -42.75M | -25.92M | -4.42M |
| EBITDA Ratio | -247.98% | -1,594.84% | -11,464.72% | 0.00% | -1,260.03% | -230.25% | 43.65% | 33.03% | -219.44% | -80.02% | -198.75% | -264.96% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -212.03M | -247.72M | -429.82M | -141.18M | -119.94M | -72.69M | -47.73M | -20.04M | -53.19M | -47.43M | -76.42M | -70.16M | -35.54M | -45.73M | -29.05M | -6.38M |
| Operating Income Ratio | -259.56% | -1,815.71% | -11,782.37% | 0.00% | -1,221.22% | -251.94% | -175.58% | -49.44% | -161.13% | -107.00% | -203.39% | -299.29% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -15.28M | 20.91M | 10.32M | 17.46M | -6.09M | 3.05M | -9.88M | 28.71M | -27.66M | 50.00K | -7.49M | -3.39M | -1.17M | 1.18M | 1.37M | 980.00K |
| Income Before Tax | -227.31M | -226.81M | -419.50M | -123.72M | -126.02M | -69.63M | -57.61M | 8.67M | -80.86M | -47.38M | -83.91M | -73.55M | -36.71M | -44.55M | -27.68M | -5.40M |
| Income Before Tax Ratio | -278.26% | -1,662.45% | -11,499.53% | 0.00% | -1,283.19% | -241.37% | -211.92% | 21.39% | -244.93% | -106.89% | -223.31% | -313.77% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 105.00K | -17.43M | 10.32M | 17.47M | -3.44M | -948.00K | -15.90M | 84.00K | -21.05M | 5.00K | -9.00K | 10.00K | 8.02M | 2.90M | 2.72M | 0.00 |
| Net Income | -227.41M | -209.38M | -419.50M | -123.91M | -126.82M | -69.71M | 26.14M | 8.59M | -80.86M | -47.39M | -83.90M | -73.56M | -45.89M | -45.57M | -27.68M | -5.40M |
| Net Income Ratio | -278.39% | -1,534.73% | -11,499.53% | 0.00% | -1,291.28% | -241.62% | 96.18% | 21.19% | -244.93% | -106.90% | -223.29% | -313.81% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.48 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| EPS Diluted | -4.24 | -3.90 | -9.74 | -3.27 | -4.65 | -2.81 | 1.22 | 0.47 | -5.96 | -4.71 | -15.72 | -141.03 | -36.50 | -272.06 | -395.43 | -108.00 |
| Weighted Avg Shares Out | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 17.83M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
| Weighted Avg Shares Out (Dil) | 53.69M | 53.69M | 43.07M | 37.89M | 27.30M | 24.79M | 21.45M | 18.13M | 13.57M | 10.07M | 5.34M | 521.63K | 1.26M | 167.50K | 70.00K | 50.00K |
2021 Top Idea Contest - New Ideas
Today, we have our "Double Down or Diversify" series. We have 13 new ideas that contributors have chosen for the second half of the contest.
Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In
Zogenix: Await Q2 Fintepla Revenue, LGS Approval Before Jumping Back In
VIP Siblings and www.vipsibling.com, New Resources to Support Brothers & Sisters of Those Living with Severe, Rare Epilepsies, Now Available from Zogenix and 10 Advocacy Groups
EMERYVILLE, Calif., July 14, 2021 (GLOBE NEWSWIRE) -- Zogenix, a global biopharmaceutical company developing rare disease therapies, and ten U.S. advocacy groups today announced the launch of VIP Siblings , a new website and suite of materials created to celebrate and deepen support for...
Zogenix's Current Price Seems Disconnected From A Strong Fintepla Launch
Zogenix's Current Price Seems Disconnected From A Strong Fintepla Launch
Zogenix to Participate in Two Upcoming Investor Conferences
EMERYVILLE, Calif., June 21, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that members of its management team will participate in two upcoming investor conferences: the Raymond James Human Health...
Zogenix to Participate in the BofA Securities 2021 Healthcare Conference
EMERYVILLE, Calif., May 11, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing and commercializing rare disease therapies, today announced that Stephen J. Farr, Ph.D., President and Chief Executive Officer, and Michael Smith, Executive Vice President, Chief Financial Officer,...
Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2021 Results - Earnings Call Transcript
Zogenix, Inc. (ZGNX) CEO Stephen Farr on Q1 2021 Results - Earnings Call Transcript
Zogenix (ZGNX) Reports Q1 Loss, Tops Revenue Estimates
Zogenix (ZGNX) delivered earnings and revenue surprises of -2.04% and 9.65%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Zogenix Q1 Earnings
Shares of Zogenix (NASDAQ:ZGNX) moved higher in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share fell 85.19% year over year to ($1.00), which beat the estimate of ($1.02).
Zogenix Presents New Data at Virtual AAN 2021 Showing Improved Executive Function in Lennox-Gastaut Syndrome (LGS) Patients Treated with FINTEPLA® (Fenfluramine) Oral Solution
EMERYVILLE, Calif., April 22, 2021 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical company developing rare disease therapies, today announced new data showing the positive impact of treatment with FINTEPLA® (fenfluramine) oral solution on everyday executive function for children...
Source: https://incomestatements.info
Category: Stock Reports
What were Zogenix’s revenue and net loss in 2021?
Net loss for the second quarter ended June 30, 2021, was $58.9 million, or a net loss of $1.05 per share compared with a net loss of $53.3 million, or a net loss of $0.96 per share, in the second quarter ended June 30, 2020. The Company recorded $32.5 million in revenue for the six months ended June 30, 2021.